Red-hot chipmaker AMD pops on surprise Q2 profit >>> READ MORE

3 Stocks to Buy in January

Biotechs and miners are starting to break out

      View All  

Stocks to Buy #2: Rosetta Genomics (ROSG)

Click to Enlarge
Rosetta Genomics (ROSG), the maker of microRNA diagnostic tests and screening tools, has cratered since going public in 2007 at a float-adjusted price of $590 per share.

ROSG stock caught fire Monday — a day after I recommended it to my clients — after Rosetta announced it had signed a service provider agreement with a major biopharmaceutical company (yet to be disclosed). That pushed ROSG stock above its 200-day moving average in a meaningful way for the first time since 2012.

Volume is pouring into ROSG as it pushes over its downtrend resistance line, and it looks ready to continue.

The catalyst seems to be the realization that the company’s microRNA cancer-finding screens are finally developing into a viable business model, with patient tissue samples flooding into its Philadelphia lab facility. In November, the number of samples received grew five-fold over the year before.

Article printed from InvestorPlace Media,

©2017 InvestorPlace Media, LLC